Chemoprevention of Prostate Cancer with 5-Alpha-Reductase Inhibitors - Marc Garnick

E. David Crawford invites Dr. Marc Garnick to review the major findings and supportive studies for the proposed use of the 5-alpha-reductase inhibitors (5-ARIs), finasteride and dutasteride, for prostate cancer chemoprevention that was rejected by the FDA in 2010.  Dr. Garnick's perspective includes his experience from  serving on the Oncologic Drugs Advisory Committee (ODAC) that reviewed the supporting data for the supplemental New Drug Applications to the FDA. The implications of the pivotall stuides for 5-ARI use as prostate cancer prevention are also discussed by Dr. Garnick. 

Dr. Garnick is Professor, Department of Medicine at Harvard Medical School, and Professor of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.